"Designing Growth Strategies is in our DNA"

Continuous Glucose Monitoring Market Size, Share & Industry Analysis, By Product Type (Sensors and Sensor Assemblies, Transmitters, Receivers and Readers, and Applicators and Accessories), By Technology (Enzymatic Electrochemical Sensing, Fluorescence-based Optical Sensing, and Others), By Clinical Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, and Others), By Distribution Channel (Retail and Specialty Pharmacies, DME and Medical Supply Distributors, Manufacturer-direct Channels, and Others), and Regional Forecast, 2026-2034

Last Updated: November 02, 2026 | Format: PDF | Report ID: FBI119304

 

Continuous Glucose Monitoring Market (2026-2034)

Play Audio Listen to Audio Version

The global continuous glucose monitoring market size was valued at USD 13.86 billion in 2025 and is projected to grow from USD 15.52 billion in 2026 to USD 33.61 billion by 2034, exhibiting a CAGR of 10.1% during the forecast period. North America dominated the continuous glucose monitoring market with a market share of 44.6% in 2025. Rising diabetes burden, broader clinical adoption of CGM across type 2 diabetes and insulin-using patients, and improving reimbursement and product access are accelerating growth in the continuous glucose monitoring market.

The continuous glucose monitoring market is entering a broader phase of clinical and commercial development. Adoption is extending beyond intensive insulin management into selected Type 2 diabetes populations. Product innovation, reimbursement policies, and digital healthcare integration are reshaping competitive priorities. Market growth will depend on clinical utility, affordability, sensor performance, and sustained access to monitoring.

The continuous glucose monitoring market size is closely linked to recurring sensor demand. Sensors generate repeat purchases through prescribed replacement cycles. Transmitters, receivers, readers, applicators, and accessories contribute additional revenue. Integrated disposable designs are changing component architectures. These systems can simplify handling while shifting revenue toward sensor assemblies.

Continuous Glucose Monitoring (CGM) systems are wearable or implantable medical devices that track glucose levels continuously or at frequent intervals, mainly through interstitial-fluid sensing, and relay readings to a receiver, smartphone, smartwatch, or connected insulin-delivery platform. CGM provides trend information, alerts, and a more complete view of glycemic patterns throughout the day and night. The market includes sensors and sensor assemblies, transmitters, receivers and readers, and applicators and accessories sold through prescription, over-the-counter, pharmacy, DME, and manufacturer-direct channels.

Market growth is being supported by the expanding diabetes population, wider reimbursement, rising use among people with type 2 diabetes, and the shift toward connected and automated diabetes management. The International Diabetes Federation estimated that 589 million adults aged 20-79 were living with diabetes in 2024, creating a large and expanding pool of potential users. Product miniaturization, longer sensor wear, simpler insertion, and smartphone connectivity are further improving acceptance.

Enzymatic electrochemical sensing dominates established commercial systems. Fluorescence-based optical sensing provides an alternative technology pathway, particularly for implantable devices. Product differentiation increasingly centers on accuracy, wear duration, calibration requirements, connectivity, and insertion experience. Compatibility with insulin pumps and automated delivery platforms also influences purchasing decisions.

Abbott Laboratories, DexCom, Inc., and Medtronic held the largest market share, driven by increased investments and strategic initiatives, including new launches, collaborations, and partnerships.

KEY TAKEAWAYS

trending up Global Market Size & Forecast
  • 2025 Market Size: USD 13.86 Billion
  • 2026 Market Size: USD 15.52 Billion
  • 2034 Forecast Market Size: USD 33.61 Billion
  • CAGR: 10.1% from 2026-2034
globe Market Share
  • The North America market dominated with a revenue share of 44.6% in 2025.
  • The sensors and sensor assemblies segment led the market by product type, supported by recurring replacement demand.
  • The type 2 diabetes segment held the largest share by clinical indication, at approximately 54.3% in 2026.
flag Key Regional Highlights

North America

North America led the global market, valued at USD 6.18 billion in 2025, supported by high diabetes prevalence, established reimbursement pathways, and rapid adoption of newer CGM technologies.

Europe

Europe is projected to reach USD 3.69 billion in 2026 and grow at a CAGR of 8.4%, driven by a large diabetes population of around 66 million adults.

Asia-Pacific

Asia-Pacific is projected to be valued at USD 3.79 billion in 2026, supported by a very large diabetes population and comparatively low CGM penetration in several major countries.

U.S.

The U.S. market is projected to reach USD 6.29 billion in 2026, capturing 40.5% of global revenues, supported by established reimbursement and strong physician acceptance.

Japan

Japan is projected to generate approximately USD 0.72 billion in 2026, contributing nearly 4.6% of global revenues.

China

China is set to reach approximately USD 1.39 billion in 2026, contributing about 9.0% of global revenues and ranking as a key national market in Asia Pacific.

Read More

arrow btn

Key Market Dynamics

Market Trends

Longer-Wear Sensors, AI-Enabled Insights, and Connected Ecosystems to Transform CGM Use

The market is moving toward longer-wear, smaller, smarter, and more connected glucose-sensing platforms. Manufacturers are extending sensor life to reduce replacement burden while embedding greater intelligence into companion applications and connected care ecosystems. Senseonics’ Eversense 365, approved in the U.S. in 2024 and commercially launched in Europe in 2026, demonstrates the shift toward year-long implantable monitoring, while newer transcutaneous systems are also extending wear duration.

The continuous glucose monitoring market is shifting toward integrated, lower-profile sensor designs. Manufacturers are reducing device size and simplifying insertion. Disposable all-in-one systems remove separate transmitter handling, changing component-level revenue structures. Longer sensor wear is another defining trend. Extended wear can reduce replacement frequency and simplify management. Implantable systems offer an alternative by reducing routine sensor changes. Adoption depends on procedure access, clinical preference, and convenience.

At the same time, software is becoming a more important part of the user experience. Dexcom introduced a generative-AI platform for Stelo in 2024 to provide more personalized glucose-related insights, reflecting the broader movement toward predictive analytics and individualized guidance. Integration with smartphones, smartwatches, insulin pumps, automated insulin-delivery systems, and cloud-based clinician platforms is also increasing. Consequently, competition is increasingly being shaped by sensor accuracy, wear convenience, interoperability, personalized interpretation, connectivity, and the ability to integrate continuous monitoring naturally into daily diabetes management.

Connectivity is becoming a core product attribute. Smartphone applications, cloud platforms, and remote data sharing support engagement between clinical visits. Clinicians can review glucose patterns remotely and identify changes requiring intervention. Interoperability is an increasingly important competitive factor. The market is expanding beyond traditional prescription pathways. Over-the-counter products create access routes for selected non-insulin users. Their positioning requires clear distinctions between wellness insights and medical functions intended to guide treatment decisions.

Market Drivers

Download Free sample to learn more about this report.

Increasing Diabetes Burden and Broader CGM Adoption to Propel Market Growth

The growing burden of diabetes, together with broader clinical use of CGM, is a central factor driving continuous glucose monitoring market growth. CGM adoption was initially concentrated among people with type 1 diabetes and those using intensive insulin therapy. Still, its role is widening across type 2 diabetes, basal-insulin users, and selected non-insulin populations. This expansion is being reinforced by easier product access, improving reimbursement, and a stronger focus on time-in-range and day-to-day glucose variability rather than isolated glucose measurements.

The continuous glucose monitoring industry benefits from a growing emphasis on glucose patterns rather than isolated measurements. Continuous data reveals overnight changes, post-meal excursions, and time outside target ranges. These insights support treatment adjustments that intermittent testing may not capture. They are particularly relevant for people using intensive insulin regimens. Automated insulin delivery is another important demand driver. These platforms rely on frequent sensor readings to inform insulin delivery. Their performance depends on dependable data transmission, sensor accuracy, and predictable operating characteristics. This relationship creates demand for compatible sensors and integrated monitoring ecosystems.

The commercial momentum of major manufacturers also reflects this wider adoption. Dexcom reported serving approximately 3.5 million customers globally at the end of 2025, while Abbott reported USD 6.8 billion in Diabetes Care revenue for 2024, with FreeStyle Libre serving as a major growth platform. As physicians increasingly use CGM data to personalize treatment and patients become more comfortable with wearable monitoring, the technology is moving from a specialized diabetes-management tool toward a broader standard of care, supporting sustained demand for sensors and related components.

The expanding focus on Type 2 diabetes management is widening the addressable patient population. Earlier monitoring can help clinicians assess treatment response and lifestyle-related glucose patterns. Adoption, however, depends on clinical suitability, affordability, and reimbursement. Broader access therefore requires differentiated products and care pathways.

Market Drivers - Impact & CAGR Contribution (2026–2034)

Rank Market Driver Overall Impact Rank CAGR Contribution (2026–2034) Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 Growth in clinical genomic testing and precision medicine High 3.10% High High High
2 Expansion of hereditary cancer, reproductive, and rare-disease counseling demand High 2.35% High High High
3 Expansion of genetic counselor capacity and hospital genetics programs Medium-High 1.95% Medium-High High High
4 Tele-genetic and digital service delivery Medium 1.55% Medium High High
5 Reimbursement expansion and national genomics initiatives Medium-Low 1.20% Medium Medium High
6 Others (cascade testing, preventive genomics, employer programs, workflow integration and awareness) Low 0.70% Low Low Medium
Total Positive Growth Contribution 10.85%  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

Market Restraints

High Recurring Costs and Uneven Reimbursement to Limit Wider Adoption

Despite strong clinical acceptance, the recurring cost of CGM remains a meaningful restraint, particularly in markets where reimbursement is limited, fragmented, or tied to narrow eligibility criteria. Continuous use requires repeated sensor purchases, while some systems also involve transmitters, receivers, insertion procedures, or subscription-related costs. For patients without adequate insurance coverage, these recurring expenses can make long-term adherence difficult, especially when lower-cost blood glucose meters remain available.

Affordability remains a restraint across the continuous glucose monitoring market. Sensors require recurring replacement, creating ongoing costs for patients and payers. Where reimbursement is limited, these expenses can restrict adoption. Even covered users may face eligibility rules, co-payments, or supply limits that interrupt use. Clinical performance also requires careful management. Sensors estimate glucose in interstitial fluid, which can lag behind blood glucose during rapid changes. Accuracy may vary with sensor age, placement, operating conditions, and individual physiology. These factors can reduce confidence and require clear guidance on interpreting readings and confirming unexpected results.

Reimbursement rules also vary considerably between countries and even across payers within the same country, creating uneven access. In the U.S., Medicare coverage of CGM supplies is linked to specific eligibility and durable medical equipment requirements. CMS states that the supply allowance is not covered when a beneficiary never uses a qualifying DME receiver or insulin infusion pump to display CGM data. These conditions can slow penetration among lower-income groups and users in less-developed reimbursement environments. Longer-wear sensors, pharmacy access, and direct-to-consumer models are helping, but affordability remains a barrier to population-level adoption.

Market Restraints - Impact & Negative CAGR Contribution (2026–2034)

Rank Market Restraints Overall Impact Rank Negative CAGR Contribution (2026–2034) Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 High recurring sensor costs and uneven reimbursement or affordability across countries and patient groups High -1.10% High High Medium
2 Sensor accuracy, reliability, skin-tolerance, adherence, and product recall-related concerns Medium-High -0.80% High Medium Medium
3 Complex regulatory, cybersecurity, interoperability, and clinical-validation requirements Medium -0.60% Medium Medium High
4 Others (pricing pressure, supply-chain interruptions, data overload, limited awareness in underpenetrated markets, switching barriers) Low -0.40% Low Low Low
Total Negative Growth Impact -2.90%  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

Market Opportunities

Expansion into Non-Insulin Type 2 Diabetes and OTC Use to Create New Revenue Opportunities

A major growth opportunity lies in extending CGM beyond the traditional insulin-treated diabetes population. Large numbers of people with type 2 diabetes who do not use insulin, along with individuals with prediabetes or other forms of dysglycemia, remain underpenetrated by continuous monitoring. Regulatory changes are beginning to open this population to new products and commercial models. In August 2024, Dexcom launched Stelo in the U.S. as an over-the-counter glucose biosensor for adults not using insulin, removing the prescription requirement for its intended population.

Type 2 diabetes represents a substantial opportunity for market expansion. Many patients do not use intensive insulin therapy but still experience variable glucose patterns. Products designed around simpler workflows, lower costs, and appropriate clinical guidance could improve access. Reimbursement and clinical evidence will determine the pace of adoption.

Emerging economies offer another growth pathway. Diabetes prevalence is increasing while digital health infrastructure and specialist services continue to develop. Local manufacturing, regional distribution partnerships, and lower-cost product configurations may improve affordability. Companies must also address reimbursement gaps and uneven clinical training.

Abbott has similarly expanded into over-the-counter monitoring with Lingo and Libre Rio, broadening glucose sensing toward diabetes management and metabolic-health applications. This creates room for manufacturers to develop consumer-facing channels, subscription programs, digital coaching tools, and pharmacy-led access models. Over time, stronger evidence around behavioral modification, treatment optimization, and earlier glycemic intervention could support wider adoption in primary care and preventive health, substantially increasing the addressable population beyond intensive insulin management.

Sensor innovation offers further differentiation. Longer wear, improved accuracy, reduced calibration burden, and better adhesive performance can strengthen product value. Implantable sensing may suit users seeking fewer routine replacements. These approaches require evidence supporting their cost and clinical positioning.

Market Challenges

Maintaining Accuracy, Reliability, and Digital Safety at Scale to Remain a Key Challenge for Manufacturers

As CGM becomes more deeply integrated into treatment decisions and automated insulin delivery, manufacturers face a growing challenge in maintaining sensor accuracy, software reliability, cybersecurity, and uninterrupted data delivery at scale. Small errors can carry greater clinical consequences when glucose readings are used to guide insulin dosing or trigger automated responses. The FDA’s 2025 correction involving certain Dexcom G7 and ONE+ applications highlighted how a software-design issue could result in missed sensor-failure alerts.

Abbott also initiated a 2025 correction for certain FreeStyle Libre 3 and Libre 3 Plus sensors after identifying the potential for incorrect low glucose readings related to a manufacturing issue. These developments underline the need for robust quality systems spanning sensor chemistry, manufacturing, firmware, mobile applications, and wireless connectivity. As portfolios expand across more countries and clinical populations, companies must also manage differing regulatory and post-market surveillance requirements. Sustaining user confidence will therefore depend on consistent real-world performance, rapid corrective action, secure connectivity, manufacturing control, and transparent communication with patients and healthcare professionals.

Market Segmentation Analysis

The continuous glucose monitoring market is segmented by product architecture, sensing technology, clinical indication, and distribution channel. Each dimension shapes purchasing behavior, recurring revenue, and competitive positioning. Product design determines replacement economics, while clinical indication influences monitoring intensity and reimbursement. Distribution structures affect affordability, supply continuity, and access to care.

By Product Type

Recurring Sensor Replacement and Expanding User Base to Keep Sensors and Sensor Assemblies Dominant

Based on product type, the market is segmented into sensors and sensor assemblies, transmitters, receivers and readers, and applicators and accessories.

Sensors and Sensor Assemblies

The sensors and sensor assemblies segment is expected to account for the largest continuous glucose monitoring market share in the coming years, as sensors are the recurring-use component of most CGM systems. Transcutaneous sensors generally require regular replacement, creating a steady replenishment cycle and high annual revenue per active user. The expanding installed CGM user base further magnifies sensor demand.

Sensors and sensor assemblies represent the principal recurring product category. Their replacement cycles create repeat demand, linking revenue to the installed user base, prescribed wear duration, and patient persistence. Sensor accuracy and reliability directly influence clinical confidence and continued use.

Manufacturers compete through wear time, insertion simplicity, adhesive performance, miniaturization, and signal stability. Smaller assemblies may improve comfort and reduce device visibility. Longer wear periods can lower replacement frequency, simplify fulfillment, and reduce the burden of routine device changes.

Integrated disposable designs combine sensing and transmission functions within a single assembly. This architecture simplifies handling and reduces dependence on separate reusable components. It also changes manufacturing economics, inventory management, and revenue allocation across product categories.

Transmitters

Transmitters convert sensor signals into data displayed through a receiver, reader, or smartphone. Their role depends on product architecture. Some systems use reusable transmitters, while integrated disposable designs incorporate transmission functions into the sensor assembly.

Reusable transmitters can generate replacement and upgrade demand. Their value depends on durability, battery performance, wireless reliability, and compatibility. Integrated systems reduce separate handling but increase the technical requirements placed on disposable units. These differences influence procurement and manufacturing decisions.

Connectivity is central to transmitter performance. Reliable communication supports alerts, remote monitoring, data sharing, and automated insulin delivery. Interruptions can weaken confidence and disrupt treatment workflows. Manufacturers must also address cybersecurity and compatibility across connected devices.

Standalone transmitter demand may decline in portfolios shifting toward all-in-one systems. However, transmitters remain relevant in architectures that separate sensing and communication. Backward compatibility can protect existing users while manufacturers introduce newer platforms.

Receivers and Readers

Receivers and readers provide dedicated interfaces for viewing glucose information. They remain relevant for users without compatible smartphones, those preferring separate medical devices, and settings requiring controlled workflows. Their importance varies with age, digital literacy, and local technology access.

Dedicated readers can simplify access for patients who do not use smartphones consistently. They may also support structured device initiation in hospitals and clinics. However, separate hardware creates procurement, inventory, and replacement requirements. Smartphone applications can reduce this burden when compatibility is reliable.

Manufacturers increasingly position readers alongside mobile applications and cloud-based reporting. Data sharing and remote review influence product design. The segment's competitiveness depends on accessibility, interface simplicity, and integration with clinical systems.

Healthcare providers may use readers during training and follow-up. A dedicated interface can support patients who need simpler workflows. However, data transfer and software updates must remain manageable. Poor integration can increase administrative workload and reduce the value of connected monitoring.

Applicators and Accessories

The applicators and accessories segment is projected to grow at a CAGR of 11.3% during the forecast period. Applicators and accessories support insertion, adhesion, protection, and routine sensor use. Their revenue contribution may be smaller than sensors, but they influence user satisfaction and persistence. Consistent insertion tools can reduce application errors and improve placement reliability.

Adhesive patches, skin barriers, overpatches, and protective accessories address practical wear challenges. Sweat, movement, bathing, and skin sensitivity can affect sensor retention. Accessories therefore support use across different activity levels and environmental conditions.

Demand generally follows sensor shipments and replacement frequency. Some accessories are bundled with devices, while others are purchased separately. Better adhesive design and simpler application can strengthen product value. Compatibility also matters when users change sensor platforms.

To know how our report can help streamline your business, Speak to Analyst

By Technology

Proven Performance and Manufacturing Scale to Sustain Enzymatic Electrochemical Sensing Leadership

By technology, the market is classified into enzymatic electrochemical sensing, fluorescence-based optical sensing, and others.

Enzymatic Electrochemical Sensing

Enzymatic electrochemical sensing is expected to hold the largest market share over the forecast period, as it underpins the dominant transcutaneous CGM platforms and combines established sensor chemistry with scalable, miniaturized electronics. The technology supports frequent glucose measurements, factory calibration, wireless transmission, and compact disposable form factors. Moreover, the segment is projected to hold a 99.6% share in 2026.

Enzymatic electrochemical sensing is the dominant technology platform across commercial continuous glucose monitoring systems. These sensors use an enzyme-mediated reaction to generate an electrical signal associated with glucose concentration. Signal-processing systems convert this response into readings for users and connected applications.

Commercial maturity supports broad deployment. Manufacturers have established production methods, regulatory experience, and clinical validation pathways. Engineering priorities include signal stability, accuracy, miniaturization, and sensor longevity. Improvements in membranes and sensor chemistry can help manage interference and performance variation.

The technology is suitable for wearable systems and established automated insulin delivery ecosystems. Clinical familiarity supports adoption among endocrinologists and diabetes care teams. However, performance depends on sensing-interface stability and consistent manufacturing quality.

Fluorescence-based Optical Sensing

The fluorescence-based optical sensing segment is estimated to grow at a CAGR of 21.6% during the forecast period. Fluorescence-based optical sensing represents a differentiated technology pathway. It uses optical responses associated with glucose concentration rather than relying solely on electrochemical measurement. The approach has been commercialized in implantable monitoring platforms.

Optical sensing may support extended sensor duration. Implantable systems can reduce the frequency of external sensor replacement. However, placement and removal require a clinical procedure. This creates a different adoption profile from wearable sensors inserted by users.

Commercial development depends on optical stability, biocompatibility, signal consistency, and reliable calibration. Long-term performance requires clinical evidence. The approach may appeal to users who prioritize fewer routine sensor replacements.

By Clinical Indication

Large Patient Pool to Drive Type 2 Diabetes Dominance

By clinical indication, the market is classified into type 1 diabetes, type 2 diabetes, gestational diabetes, and others.

Type 1 Diabetes

Type 1 diabetes is a foundational indication for continuous glucose monitoring. Patients generally require ongoing insulin therapy and frequent glucose assessment. Continuous data supports insulin adjustment, hypoglycemia detection, and evaluation of time spent within target ranges.

Demand is supported by clinical familiarity and integration with insulin pumps. Automated insulin delivery systems rely on continuous sensor inputs. This creates a strong relationship between sensor adoption and connected insulin technologies.

Pediatric use is also important. Caregivers may use remote monitoring features to review glucose patterns and respond to alerts. This increases the value of reliable connectivity and data sharing. Device comfort and adhesive performance remain important for long-term use.

The segment is relatively mature in several developed markets. Future growth will depend on improved access, product upgrades, and broader reimbursement. Accuracy and interoperability will remain key purchasing considerations.

Type 1 users often depend on continuous data throughout the day and night. Sensor interruptions can complicate insulin management. Reliability and alert performance therefore carry substantial clinical importance. Manufacturers must maintain dependable supply and technical support.

The indication also supports integrated technology ecosystems. Compatibility between sensors, pumps, and algorithms can reduce manual intervention. However, interoperability remains a competitive and regulatory consideration. Connected components must demonstrate reliable performance as a system.

Type 2 Diabetes

Type 2 diabetes is expected to hold the largest share over the forecast period, as it represents the largest diabetes population and CGM use is extending well beyond intensive insulin therapy. Moreover, the segment is projected to hold a 54.3% share in 2026.

Type 2 diabetes offers a broad opportunity because its patient population is substantially larger than the Type 1 population. Adoption behavior, however, is more varied. Monitoring needs differ according to disease duration, treatment intensity, hypoglycemia risk, and clinical objectives.

Patients using intensive insulin regimens are an established user group. Wider adoption among people using basal insulin or non-insulin therapies requires evidence of clinical and economic value. Simpler devices and lower recurring costs may improve uptake.

Continuous monitoring can help clinicians assess responses to medication, diet, and physical activity. It may also reveal glucose variability that periodic testing does not capture. Monitoring frequency should align with treatment goals and individual clinical needs.

Over-the-counter products may broaden access among selected non-insulin users. Their positioning must remain distinct from devices intended to guide insulin dosing. Expansion depends on reimbursement, clinical guidance, affordability, and responsible communication.

Gestational Diabetes

The gestational diabetes segment is estimated to grow at a CAGR of 12.2% during the forecast period. Gestational diabetes is a targeted clinical application with distinct monitoring requirements. Maternal glucose control is important during pregnancy. Continuous monitoring may provide additional information about daily glucose patterns and treatment response.

Adoption is influenced by obstetric practice, endocrinology support, and local clinical protocols. Some care pathways continue to rely primarily on capillary blood glucose testing. Wider use requires evidence that continuous data improves relevant maternal or neonatal outcomes.

Shorter treatment periods create a different demand pattern from lifelong diabetes management. Sensor supply must align with pregnancy duration and clinical need. Cost and reimbursement can determine whether monitoring is routine or selective.

The segment offers an opportunity for targeted clinical validation. Device comfort, accuracy, and ease of use are important during pregnancy. Clear guidance is necessary because treatment decisions may depend on specific clinical thresholds.

By Distribution Channel

Convenient Access and Expanding Consumer Availability to Boost Retail and Specialty Pharmacies Segment Growth

On the distribution channel, the market is classified into retail and specialty pharmacies, DME and medical supply distributors, manufacturer-direct channels, and others.

Retail and Specialty Pharmacies

Retail and specialty pharmacies are expected to account for the largest share over the forecast period, as CGM shifts from a specialist-device model toward routine outpatient diabetes management. Pharmacy access reduces procurement friction, allows patients to obtain sensors alongside other diabetes therapies, and can simplify access compared with traditional equipment channels. Furthermore, the segment is set to hold a 48.9% share in 2026.

Retail and specialty pharmacies provide established routes for sensor dispensing and recurring refills. Specialty pharmacies can assist with prior authorization, benefits verification, and product education. Reliable inventory and refill coordination help prevent monitoring interruptions. Over-the-counter products may further expand retail participation, although consumer guidance and appropriate product positioning remain essential.

DME and Medical Supply Distributors

Durable medical equipment (DME) and medical supply distributors serve patients whose coverage routes devices through equipment benefits. They manage documentation, eligibility checks, fulfillment, and recurring shipments. Payer relationships and administrative expertise support their position. Delays in authorization or delivery can interrupt sensor use and weaken patient retention.

Manufacturer-direct Channels

The manufacturer-direct channels segment is projected to grow at a CAGR of 13.8% during the forecast period. Manufacturer-direct channels allow companies to manage sales, subscriptions, education, and customer relationships. Digital ordering can simplify repeat purchases, particularly for cash-pay and selected consumer products. Direct distribution requires investment in logistics, service, and compliance. Manufacturers must balance channel control with established pharmacy and distributor relationships.

Regional Insights

Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America Continuous Glucose Monitoring Market Analysis

North America Continuous Glucose Monitoring Market Size, 2025 (USD Billion)

To get more information on the regional analysis of this market, Download Free sample

North America held the largest revenue share in 2024, at USD 5.45 billion, and was valued at USD 6.18 billion in 2025. Market growth is supported by high diabetes prevalence, established reimbursement pathways, strong physician acceptance, and rapid adoption of newer CGM technologies in the U.S. and Canada. The International Diabetes Federation projects the number of people with diabetes in the North America & Caribbean region to increase by approximately 22% by 2050, sustaining the long-term addressable patient base.

North America benefits from established diabetes technology adoption, specialist care networks, and developed reimbursement systems. The United States drives regional demand, while Canada contributes through public and private coverage pathways. Competition centers on accuracy, integration, and recurring supply. Access remains uneven across payer groups. Future growth depends on broader Type 2 diabetes adoption, affordability, and sustained reimbursement support. 

United States Continuous Glucose Monitoring Market

In 2026, the U.S. market is projected to represent USD 6.29 billion, capturing 40.5% of total global revenues. The United States is a leading commercial market, supported by clinical awareness and established device manufacturers. Medicare and private payer policies influence eligibility and channel selection. Over-the-counter clearances are expanding selected access pathways. Competition is intensifying around integrated systems, sensor duration, and consumer positioning. Coverage restrictions and out-of-pocket costs continue to shape adoption among non-intensive insulin users.

Europe Continuous Glucose Monitoring Market Analysis

Europe is expected to achieve a CAGR of 8.4% in the coming years, the second-highest globally, reaching USD 3.69 billion in 2026. The IDF estimates that around 66 million adults in Europe are living with diabetes, with the number expected to increase by about 10% by 2050, providing a sustained clinical demand base.

Europe combines mature diabetes technology markets with varied national reimbursement systems. Adoption is supported by public healthcare infrastructure and specialist diabetes services. Procurement decisions differ across countries, affecting pricing and product access. Manufacturers must demonstrate clinical value and cost-effectiveness. Growth opportunities include wider Type 2 diabetes use, improved interoperability, and expanded access in markets with lower technology penetration.

Germany Continuous Glucose Monitoring Market

The market in Germany is projected to reach about USD 0.70 billion in 2026, representing roughly 4.5% of global revenues. Germany benefits from a developed medical technology sector and established diabetes care infrastructure. Reimbursement rules and statutory health insurance decisions influence access. Specialist practices and diabetes centers support device education and treatment integration. Competition focuses on product performance, service reliability, and compatibility with insulin delivery systems. Future adoption will depend on clinical evidence, coverage decisions, and patient affordability.

United Kingdom Continuous Glucose Monitoring Market

The U.K. market is projected to reach USD 0.55 billion in 2026, accounting for 3.5% of global revenues. The United Kingdom's market is shaped by National Health Service procurement, clinical guidance, and regional implementation. Access varies according to eligibility criteria and local service capacity. Established diabetes technology pathways support adoption among insulin-treated patients. Wider use requires budget justification and clinical workforce support. Product suppliers must address procurement value, interoperability, and equitable access across healthcare systems.

Asia-Pacific Continuous Glucose Monitoring Market Analysis

In 2026, the Asia Pacific market is predicted to be valued at USD 3.79 billion, ranking as the third-largest globally. The market offers substantial growth potential, as it combines an exceptionally large diabetes population with comparatively lower CGM penetration in several major countries.

Asia-Pacific offers substantial long-term potential due to diabetes prevalence, expanding healthcare capacity, and rising digital health adoption. Market maturity varies widely between countries. Japan, China, and Australia have distinct reimbursement and regulatory environments. Affordability remains a central constraint. Local manufacturing, clinician education, and partnerships may improve access and support regional market growth. The market in India is set to reach approximately USD 0.43 billion in 2026, corresponding to about 2.8% of global revenues.

Japan Continuous Glucose Monitoring Market

The market in Japan is projected to generate approximately USD 0.72 billion in 2026, contributing nearly 4.6% of global revenues. Japan has advanced medical technology capabilities and an established diabetes care system. Clinical adoption is influenced by physician guidance, reimbursement, and product usability. Demand includes patients requiring intensive insulin management and those benefiting from closer glucose assessment. Manufacturers must meet stringent regulatory and quality expectations. Compact designs, reliable performance, and integration with digital care may support future expansion.

China Continuous Glucose Monitoring Market

The market in China is set to reach approximately USD 1.39 billion in 2026, contributing about 9.0% of global revenues. China represents a significant opportunity because of its large diabetes population and expanding medical device sector. Adoption is influenced by affordability, hospital access, and regional reimbursement differences. Domestic manufacturers are increasing competition through local product development and distribution. Clinical education remains important. Market growth will depend on reliable sensor supply, regulatory compliance, and broader access beyond major urban centers.

Latin America Continuous Glucose Monitoring Market Analysis

Latin America and the Middle East & Africa are anticipated to witness moderate market growth, with Latin America expected to reach around USD 0.70 billion in 2026. The Latin America market is expected to grow from a comparatively smaller base as the diabetes burden rises and advanced glucose-monitoring technologies become more accessible in major markets such as Brazil and Mexico. The Middle East & Africa market is expected to expand as a high and rapidly increasing diabetes burden combines with relatively low current penetration of advanced glucose-monitoring technologies.

Latin America's market remains uneven due to differences in healthcare funding, insurance coverage, and specialist access. Private healthcare demand is more developed in selected urban markets. Public procurement and reimbursement can influence broader adoption. Price-sensitive purchasing favors affordable systems and dependable distribution. Local partnerships, clinician training, and improved coverage could strengthen access over the forecast period. 

The Middle East and Africa show varied adoption, shaped by healthcare investment and purchasing power. Gulf markets benefit from advanced hospitals and private care capacity. Other countries face affordability and distribution constraints. Demand is supported by diabetes management needs. Wider access requires local partnerships, clinician education, reimbursement development, and reliable supply chains.

GCC Continuous Glucose Monitoring Market

In 2026, the GCC market is expected to generate approximately USD 0.20 billion, accounting for nearly 1.3% of global revenues.

Continuous Glucose Monitoring Industry Competitive Landscape

Strong Market Concentration and Continuous Product Innovation to Intensify Competition

The global continuous glucose monitoring market has a relatively concentrated competitive structure, led primarily by Abbott Laboratories, DexCom, Inc., and Medtronic, which benefit from large installed user bases, established reimbursement access, extensive distribution networks, and strong integration with digital diabetes-management ecosystems.

  • For instance, Abbott’s FreeStyle Libre platform has more than 7 million users globally, while Dexcom generated USD 4.66 billion in revenue in 2025, highlighting the commercial scale of the leading participants.

Competition is increasingly shifting beyond basic glucose-monitoring accuracy toward longer sensor wear, smaller form factors, lower cost, factory calibration, smartphone connectivity, OTC availability, predictive analytics, and interoperability with automated insulin-delivery systems. Roche is strengthening competition through its AI-enabled Accu-Chek SmartGuide, while Senseonics differentiates itself through the 365-day implantable Eversense system. Regional manufacturers, particularly from Asia, are also increasing pricing pressure and expanding CGM availability, making technological differentiation, reimbursement access, manufacturing scale, and geographic expansion increasingly important competitive factors.

The continuous glucose monitoring industry is led by companies with established sensor platforms, regulatory experience, clinical evidence, and global distribution. Abbott and Dexcom hold prominent positions in wearable sensor systems. Their strategies emphasize accuracy, ease of use, product breadth, and recurring sensor sales. Both companies are pursuing opportunities beyond traditional intensive insulin management.

Medtronic occupies an important position through its diabetes technology ecosystem. Its competitive proposition connects continuous monitoring with insulin pumps, smart pens, and automated insulin delivery. Partnerships can expand product choice while strengthening platform integration. Its collaboration with Abbott illustrates the strategic value of combining sensor technology with insulin delivery expertise.

Senseonics differentiates through implantable, long-duration sensing. Its Eversense platform targets users seeking fewer routine sensor replacements. The model depends on clinical procedures and trained providers. This creates a distinct commercial pathway from disposable wearable systems.

LIST OF KEY CONTINUOUS GLUCOSE MONITORING COMPANIES PROFILED

  • Abbott Laboratories (U.S.)
  • DexCom, Inc. (U.S.)
  • Medtronic plc (Ireland)
  • Senseonics Holdings, Inc. (U.S.)
  • Sinocare Inc. (China)
  • Shenzhen SiBionics Technology Co., Ltd. (China)
  • MicroTech Medical (Hangzhou) Co., Ltd. (China)
  • Medtrum Technologies Inc. (China)
  • i-SENS, Inc. (South Korea)
  • Infinovo Medical Co., Ltd. (China)

Latest Continuous Glucose Monitoring Industry Developments (2025–2026)

  • September 2026: Biolinq: The company received U.S. Food and Drug Administration (FDA) 510(k) clearance for over-the-counter use of its Shine glucose sensor. The needle-free wearable combines semiconductor-based microsensors with glucose, activity, and sleep insights. Its integrated display communicates glucose ranges without requiring a smartphone. The clearance supports Biolinq's strategy to enter the consumer metabolic health segment. The product is intended for adults not using insulin and is not designed for insulin dosing or acute treatment decisions. 
  • August 2026: Abbott and Google Health: The companies announced a multi-year partnership integrating glucose insights from Abbott's Lingo biowearable with Google Health technology. The collaboration aims to combine glucose trends with broader health information and provide personalized, artificial intelligence-powered guidance. A large-scale research study will examine relationships between glucose, activity, sleep, and wellbeing. The initiative expands CGM-related data applications into preventive health and digital coaching. 
  • June 2026: Dexcom: The company received FDA clearance expanding the Stelo over-the-counter glucose biosensor indication to children aged two years and older who do not use insulin. The system combines a wearable sensor with a compatible smartphone application and supports caregiver access. The expansion uses clinical study data and real-world evidence. It extends glucose biosensing into pediatric metabolic health monitoring, subject to specified use limitations. 
  • January 2026: Senseonics and Sequel MedTech: The companies began commercial use of the Eversense 365 continuous glucose monitor with Sequel's twiist automated insulin delivery system. The integration connects a one-year implantable sensor with an insulin pump and automated dosing algorithm. It reduces routine sensor replacement and pairing requirements while expanding patient choice. The partnership strengthens the role of long-duration implantable sensing within connected insulin delivery ecosystems. 
    Senseonics
  • September 2025: Medtronic: The company received FDA clearance for its SmartGuard algorithm as an interoperable automated glycemic controller, enabling integration of Abbott's Instinct continuous glucose monitoring sensor with the MiniMed 780G system. The FDA also approved the system for adults with insulin-requiring Type 2 diabetes. The development expands sensor compatibility and broadens the addressable population for automated insulin delivery.

REPORT COVERAGE 

The report provides an in-depth analysis of all continuous glucose monitoring market segments, highlighting key drivers, trends, opportunities, restraints, and challenges. It also provides insights into technological advancements, key industry developments, company market share analysis, and profiles of leading companies. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope and Segmentation

ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year 2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 10.1% from 2026 to 2034
Unit Value (USD Billion)
Segmentation By Product Type, By Technology, By Clinical Indication, By Distribution Channel, and Region
By Product Type
  • Sensors and Sensor Assemblies
  • Transmitters
  • Receivers and Readers
  • Applicators and Accessories
By Technology
  • Enzymatic Electrochemical Sensing
  • Fluorescence-based Optical Sensing
  • Others
By Clinical Indication
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Others
By Distribution Channel
  • Retail and Specialty Pharmacies
  • DME and Medical Supply Distributors
  • Manufacturer-direct Channels
  • Others
By Region
  • North America (By Product Type, By Technology, By Clinical Indication, By Distribution Channel, and By Country)
    • U.S. (By Product Type)
    • Canada (By Product Type)
  • Europe (By Product Type, By Technology, By Clinical Indication, By Distribution Channel, and By Country/Sub-region)
    • Germany (By Product Type)
    • U.K. (By Product Type)
    • France (By Product Type)
    • Spain (By Product Type)
    • Italy (By Product Type)
    • Scandinavia (By Product Type)
    • Rest of Europe (By Product Type)
  • Asia Pacific (By Product Type, By Technology, By Clinical Indication, By Distribution Channel, and By Country/Sub-region)
    • China (By Product Type)
    • Japan (By Product Type)
    • India (By Product Type)
    • Australia (By Product Type)
    • Southeast Asia (By Product Type)
    • Rest of Asia Pacific (By Product Type)
  • Latin America (By Product Type, By Technology, By Clinical Indication, By Distribution Channel, and By Country/Sub-region)
    • Brazil (By Product Type)
    • Mexico (By Product Type)
    • Rest of Latin America (By Product Type)
  • Middle East & Africa (By Product Type, By Technology, By Clinical Indication, By Distribution Channel, and By Country/Sub-region)
    • GCC (By Product Type)
    • South Africa (By Product Type)
    • Rest of Middle East & Africa (By Product Type)

Bottom-Up Approaches

Approach 1: Revenues and Market Share of Major CGM Players

  • Collection of CGM-specific revenues from annual reports, SEC filings, investor presentations, earnings releases, and official company disclosures of Abbott, Dexcom, Medtronic, Senseonics, Sinocare, and other manufacturers.
  • Estimation of company market shares based on CGM revenues, geographic presence, product portfolio, installed user base, and commercial availability.
  • Triangulation of company-level revenues with regional and country-level CGM adoption to derive the global market estimate.

Approach 2: Product Volume, Replacement Cycle, and Pricing Analysis

  • Identification of major CGM products and estimation of sensor, transmitter, receiver, and accessory volumes across key countries.
  • Assessment of sensor wear duration, annual replacement frequency, active user base, and manufacturer-level average selling prices.
  • Multiplication of estimated product volumes by manufacturer selling prices, followed by aggregation across countries and regions to derive market value.

Approach 3: Patient Eligibility and CGM Adoption Model

  • Assessment of diagnosed and CGM-eligible populations across Type 1 diabetes, Type 2 diabetes, gestational diabetes, and other clinical indications.
  • Mapping of CGM penetration based on insulin use, treatment intensity, reimbursement coverage, affordability, and product availability.
  • Multiplication of active CGM users by annual device consumption and average manufacturer-level expenditure to estimate country and regional markets.

Top-Down Approach

Approach 1: Country-Level Diabetes Burden and CGM Penetration Analysis

  • Analysis of diabetes prevalence, diagnosed patient population, insulin-treated population, healthcare expenditure, reimbursement, and technology adoption across key countries.
  • Estimation of the proportion of eligible patients using CGM based on clinical guidelines, reimbursement policies, product availability, and market maturity.
  • Aggregation of country-level CGM demand estimates and validation against company revenues and product-volume calculations to derive regional and global market size.

List of Key Sources

  • International Diabetes Federation, WHO, CDC, ADA, EASD, national diabetes registries, and national health ministries.
  • FDA, European Commission, PMDA/MHLW, NMPA, CDSCO, TGA, CMS, NICE/NHS, NDSS, and other regulatory and reimbursement authorities.
  • Annual reports, SEC/stock-exchange filings, investor presentations, earnings releases, company press releases, product labels, regulatory approvals, and product catalogs.
  • CGM user-base disclosures, sensor wear duration, product launches, reimbursement changes, geographic expansions, partnerships, and manufacturing-capacity announcements.

Primary Interviews

Supply-Side Interviews: 60%

  • Key Respondents: CGM manufacturers, sensor/component suppliers, distributors, DME suppliers, pharmacy-channel participants, sales executives, marketing managers, and market-access professionals.
  • Interviews will validate market size, pricing, product volumes, replacement frequency, distribution mix, competitive positioning, and regional growth trends.

Demand-Side Interviews: 40%

  • Key Respondents: Endocrinologists, diabetologists, diabetes educators, healthcare providers, procurement professionals, payers, and reimbursement experts.
  • Interviews will assess CGM penetration, patient eligibility, prescribing patterns, reimbursement access, treatment preferences, affordability, and adoption across countries and clinical indications.

Final Market Triangulation

  • Results from company-revenue analysis, product-volume analysis, patient-adoption modeling, country-level analysis, secondary research, and primary interviews will be compared and reconciled.
  • Manufacturer-level revenues will be used as the final valuation basis. In contrast, distributor margins, pharmacy markups, healthcare-service revenues, and insulin-pump revenues outside the identifiable CGM component will be excluded to prevent double counting.

 



Frequently Asked Questions

Fortune Business Insights says that the global market value stood at USD 13.86 billion in 2025 and is projected to reach USD 33.61 billion by 2034.

In 2025, the market value in North America stood at USD 6.18 billion.

The market is expected to exhibit a CAGR of 10.1% during the forecast period of 2026-2034.

By product type, the sensors and sensor assemblies segment is expected to lead the market over the forecast period.

The key factors driving the market are the rising diabetes burden and broader CGM adoption.

Abbott Laboratories, DexCom, Inc., and Medtronic are some of the major players in the market.

North America dominated the market in 2025.

Seeking Comprehensive Intelligence on Different Markets?Get in Touch with Our Experts Speak to an Expert
  • 2021-2034
  • 2025
  • 2021-2024
  • 220
Download Free Sample

    man icon
    Mail icon
    Mail icon
Jump to Content

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Healthcare Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann